1.Deterding, K et al. (2017) Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infectious Diseases 17, 215–222.
2.Feld, JJ et al. (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine 373, 2599–2607.
4.Cohen, MS et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 365, 493–505.
5.Granich, RM and Williams, B (2016) HIV treatment: time to lean forward. The Lancet 387, 27.
6.Grebely, J and Dore, GJ (2014) Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Research 104, 62–72.
7.Bruggmann, P and Grebely, J (2015) Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26, S22–S26.
8.Gornall, J, Hoey, A and Ozieranski, P (2016) A pill too hard to swallow: how the NHS is limiting access to high priced drugs. The British Medical Journal 4117, i4117.
9.Innes, H et al. (2014) Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut 64, 1800–1809.
10.Martin, NK et al. (2013) Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 57(Suppl. 2), S39–S45.
11.Martin, NK, Vickerman, P and Hickman, M (2011) Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology 274, 58–66.
12.Miller, ER et al. (2009) Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. Journal of Infection 58, 375–382.
13.Newman, MEJ (2002) Assortative mixing in networks. Physical Review Letters 89, 208701.
14.Garnett, GP and Anderson, RM (1993) Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philosophical Transactions of the Royal Society of London 342, 137–159.
15.Anderson, RM et al. (1992) Age-dependent choice of sexual partners and the transmission dynamics of HIV in Sub-Saharan Africa. Philosophical Transactions of the Royal Society of London 336, 135–155.
16.Thomas, DL et al. (1995) Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 74, 212–220.
17.Alter, MJ and Moyer, LA. (1998) The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndrome 18(Suppl. 1), S6–10.
18.Garfein, RS et al. (1996) Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health 86, 655–661.
19.Read, JM, Eames, KTD and Edmunds, WJ (2008) Dynamic social networks and the implications for the spread of infectious disease. Journal of the Royal Society Interface 5, 1001–1007.
20.Tobin, KE et al. (2011) The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction 106, 366–375.
21.Celentano, DD et al. (1991) Risk factors for shooting gallery use and cessation among intravenous drug users. American Journal of Public Health 81, 1291–1295.
22.Williams, ML et al. (1995) A comparison of drug use networks across three cities. NIDA Research Monograph Series: Social Networks, Drug Abuse and HIV Transmission 151, 109–130.
23.Mossong, J et al. (2008) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Medicine 5, e74.
25.Read, JM et al. (2014) Social mixing patterns in rural and urban areas of southern China. Proceedings of the Royal Society 281, 20140268.
26.Danon, L et al. (2012) Social encounter networks: collective properties and disease transmission Supplementary Material. Journal of the Royal Society Interface 9, 2826–2833.
27.Horby, P et al. (2011) Social contact patterns in Vietnam and implications for the control of infectious diseases. PLoS ONE 6, 1–7.
28.Barnabas, RV et al. (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Medicine 3, 624–632.
29.Aral, SO et al. (1999) Sexual mixing patterns in the spread of gonococcal and chlamydial infections. American Journal of Public Health 89, 825–833.
30.Bailey, SL et al. (2007) Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five US cities. Drug and Alcohol Dependence 91, S18–S29.
31.Becker Buxton, M et al. (2004) Association between injection practices and duration of injection among recently initiated injection drug users. Drug and Alcohol Dependence 75, 177–183.
32.Neaigus, A et al. (1996) High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. Journal of Acquired Immune Deficiency Syndrome 11, 499–509.
33.Garfein, RS et al. (1998) Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndrome 18, S11–S19.
35.Page, K et al. (2013) Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clinical Infectious Diseases 57(Suppl. 2), S32–S38.
36.Harris, M, Albers, E and Swan, T. (2015) The promise of treatment as prevention for hepatitis C: meeting the needs of people who inject drugs? International Journal of Drug Policy 26, 963–969.
37.Cheung, R, Mannalithara, A and Singh, G (2010) Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US. Digestive Diseases and Sciences 55, 1744–1751.
38.Strathdee, SA et al. (1998) Barriers to use of free antiretroviral therapy in injection drug users. Journal of the American Medical Association 280, 547–549.
39.Stimson, GV (1989) Syringe-exchange programmes for injecting drug users. AIDS (London, England) 3, 253–260.
40.De, P et al. (2007) The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction 102, 1730–1739.
41.Cicero, TJ et al. (2014) The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71, 821–826.